Omsk Hemorrhagic Fever Virus and Powassan Virus Infections at Different Times After Immunization with the TBE Vaccine in In Vivo Experiments
International Journal of Molecular Sciences · 16.06.2026 · 27 (12) · 5435
DOI: 10.3390/ijms27125435 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.06.2026. Verfasst von Viktoria Kuchina und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biology of Arboviruses, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Ac…. Hauptthemen laut MEDLINE: Encephalitis Viruses, Tick-Borne, Viral Vaccines, Encephalitis, Tick-Borne. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis) fundamental research assignment, Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis) fundamental research assignment.
Abstract (Originalsprache)
Ranges of distribution of some orthoflaviviruses, including the Omsk hemorrhagic fever virus (OHFV) and the Powassan virus (POWV), have been identified in the range endemic for the tick-borne encephalitis virus (TBEV). In contrast to TBEV, no registered vaccine against OHFV and POWV is currently available. Nevertheless, recent studies have indicated that the anti-TBEV vaccine may offer partial protection against other orthoflaviviruses. The present study assesses OHFV and POWV infection in an experimental model on BALB/c mice one, three- and twelve-months post-immunization with inactivated TBE vaccine. The TBE vaccine was shown to provide long-term protection against OHFV and partial protection against POWV, even in the absence of specific antibodies, and without indications of antibody-dependent enhancement of infection. The neutralizing antibody titer for OHFV in vaccinated animals before and after the challenge with OHFV was similar to the titer of antibodies against the TBEV vaccine strain. Following immunization with anti-TBEV vaccine and subsequent inoculation of POWV, the levels of neutralizing antibodies against the TBEV vaccine strain was observed to be higher compared to those targeting POWV, especially during the initial phase of infection. Such cross-reactive antibodies have potential to pose a significant diagnostic challenge in cases where an infection is occurring simultaneously with an immune response to another virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biology of Arboviruses, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow 108819, Russia.
- Faculty of Biology, Lomonosov Moscow State University, Moscow 119234, Russia.
- Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia.
ORCID-Profile: Viktoria Kuchina, Ksenia Tuchynskaya, Galina Karganova
Förderung
- Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis) fundamental research assignment
- Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis) fundamental research assignment
Zitieren
APA
Kuchina, V., Tuchynskaya, K., Rogova, A., & Karganova, G. (2026). Omsk Hemorrhagic Fever Virus and Powassan Virus Infections at Different Times After Immunization with the TBE Vaccine in In Vivo Experiments. International Journal of Molecular Sciences, 27(12), 5435. https://doi.org/10.3390/ijms27125435
Vancouver
Kuchina V, Tuchynskaya K, Rogova A, Karganova G. Omsk Hemorrhagic Fever Virus and Powassan Virus Infections at Different Times After Immunization with the TBE Vaccine in In Vivo Experiments. International Journal of Molecular Sciences. 2026;27(12):5435. doi:10.3390/ijms27125435
BibTeX
@article{Kuchina2026,
author = {Kuchina, Viktoria and Tuchynskaya, Ksenia and Rogova, Anastasia and Karganova, Galina},
title = {Omsk Hemorrhagic Fever Virus and Powassan Virus Infections at Different Times After Immunization with the TBE Vaccine in In Vivo Experiments},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5435},
doi = {10.3390/ijms27125435}
}
EUVIMED